Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?

Anne-Sophie Bargnoux (1, 2) , Nils Kuster (1, 2) , Laure Patrier , Anne-Marie Dupuy (3) , Gaelle Tachon (4) , François Maurice (5) , Bouchra Badaoui (6) , Lotfi Chalabi (7) , Stéphanie Badiou (2, 1) , Sébastien Deleuze (8) , Hélène Leray-Moragues (2) , Marion Morena (2, 1) , Bernard Canaud (2) , Jean-Paul Cristol (2, 1)

1 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
2 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
3 Département de biochimie [Montpellier]
4 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
5 CHLM - Centre hémodialyse Languedoc Méditerranée
6 CHU Henri Mondor [Créteil]
7 AIDER - Association Installation à Domicile Epurations Rénales
8 Centre Hémodialyse Languedoc Méditerranée

Domaines: Sciences du Vivant [q-bio]

Anne-Sophie Bargnoux, Nils Kuster, Laure Patrier, Anne-Marie Dupuy, Gaelle Tachon, et al.. Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?. Clinical Chemistry and Laboratory Medicine, 2016, 54 (4), pp.673-82. ⟨10.1515/cclm-2015-0071⟩. ⟨hal-01803061⟩